Cell depleting experiments showed that tumor protection wasdependent on the CD4+ and CD8+ T cells as removal ofCD4+ or CD8+ T cells abrogated the antitumor effectconferred by anti-PD-1/GITR mAb treatment (Figure 1F). Here, TNFRSF18 is linked to neoplasm.